33例膀胱内灌注吡柔比星预防浅表性膀胱癌术后复发疗效观察

目的评价吡柔比星(THP)膀胱内灌注预防浅表性膀胱癌术后复发的近期疗效和不良反应。方法对33例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术(TURBT),术后2周THP30mg膀胱灌注,每周1次,共8次;以后每月1次,共10个月,随访期间内行膀胱镜检查。结果30例可评价疗效,无肿瘤复发28例,复发2例,复发率为6.7%;发生不良反应者12例(40.0%),均为不同程度膀胱刺激症状。结论THP膀胱内灌注预防浅表性膀胱癌术后复发近期疗效满意,不良反应小,耐受性良好。

Intravesical instillation of pirarubicin for preventing postoperative recurrence of superficial bladder cancer in 33 patients

Objective To evaluate the efficacy and safety of intravesical instillation of pirarubicin (THP) for preventing postoperative recurrence of superficial bladder cancer.Methods Thirty-three patients with superficial transitional cell bladder cancer who were suitable to the inclusion criteria were enrolled in this study.THP (30mg/50ml of normal saline) was instilled intravesically within two weeks after operation once a week for eight weeks,followed by once a month till one year.Regular cystoscopy was performed during the follow-up.Results Thirty patients were followed up for 12 months.Tumor recurrence was found in 2 cases and the total recurrence rate was 6.67%.Urinary irritation and abnormal urine analysis were the predominant adverse reactions.Conclusion Intravesical administration of THP after operation was effective and well-tolerated for preventing tumor recurrence.